Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
TXG
HoldPremium Grower10x Genomics, Inc. · Healthcare · United States · $8.0B · Avg Vol: $184M/d
COMPANY DESCRIPTION
10x Genomics, Inc. develops and sells integrated systems, including instruments, consumables, and software, for advanced genomic analysis, specializing in single-cell and spatial biology. The company's competitive moat is derived from its proprietary technology platforms, which provide unprecedented resolution in biological research, establishing it as a market leader in these rapidly expanding fields. 10x Genomics is a key enabler for breakthroughs in genomics and biomedical discovery.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 516.4M | 618.7M | 610.8M | 642.8M | 7.6% | 616.9M | 620.4M | 679.9M | 2.8% |
| EPS | -1.46 | -2.18 | -1.52 | -0.35 | — | -0.59 | — | — | — |
| Shares | 115.2M | 119.1M | 122.3M | 127.7M | +10.8% | 120.2M | — | — | — |
| Debt | 95.2M | 95.4M | 82.6M | 84.4M | -3.9% | 78.8M | — | — | — |
| Equity | 805.7M | 741.0M | 710.1M | 796.3M | -0.4% | — | — | — | — |
| Op CF | -33.6M | -15.2M | 6.7M | 136.1M | 1941.6% | 127.1M | — | — | — |
| Inv CF | -350.9M | 133.5M | -32.6M | -13.4M | — | — | — | — | — |
| Fin CF | 15.8M | 13.7M | 10.9M | 6.8M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of TXG are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| TXG | 10x Genomics, Inc.(you) | $8.0B | 60 | Hold |
| DOCS | Doximity, Inc. | $4.8B | 61 | Hold |
| WAY | Waystar Holding Corp. | $5.0B | 62 | Hold |
| HQY | HealthEquity, Inc. | $8.0B | 82 | Strong Buy |
| HNGE | Hinge Health, Inc. | $7.0B | 84 | Strong Buy |
| HTFL | Heartflow, Inc. | $4.2B | 44 | Hold |
| BTSG | BrightSpring Health Services, Inc. | $11.7B | 84 | Strong Buy |
| PRVA | Privia Health Group, Inc. | $2.7B | 51 | Hold |
| TEM | Tempus AI, Inc. | $11.6B | 31 | Sell |
| OMDA | Omada Health, Inc. | $1.5B | 65 | Buy |
Peer medians: ROE -30.8% · P/E 27.0x · Gross margin 58.1%